Results of a fludarabine induction and α-interferon maintenance protocol in pretreated patients with chronic lymphocytic leukemia and low-grade non-Hodgkin's lymphoma-Reference-Cited by-同舟云学术

Results of a fludarabine induction and α-interferon maintenance protocol in pretreated patients with chronic lymphocytic leukemia and low-grade non-Hodgkin's lymphoma

Published:2009-04-24 Issue:2 Volume:59 Page:82-88
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:

Author:

Zinzani P. L.,Bendandi M.,Magagnoli M.,Rondelli D.,Vivo A.,Benni M.,Zamagni E.,Cavo M.,Tura S.

Publisher

Wiley

Subject

Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1600-0609.1997.tb00730.x/fullpdf

Reference32 articles.

1. Pharmacokinetic study of fludarabine phosphate (NSC 312887);Hersh;Cancer Chemother Pharmacol,1986

2. Specificity of systems mediating transport of adenosin e 9-a-D- arabi-nofuranosyl-2-fluoroadenine, and other purine nucleoside analogues in L1210 cells;Sirotnak;Cancer Res,1983

3. Fludarabine monophosphate: a potentially useful agent in chronic lymphocytic leukemia;Grever;Nouv Rev Fr Hematol,1988

4. Fludarabine: a new agent with major activity against chronic lymphocytic leukemia;Keating;Blood,1989

5. Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia;Keating;J Clin Oncol,1991

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Maintenance therapy for chronic lymphocytic leukaemia;Cochrane Database of Systematic Reviews;2024-01-04

2. Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia;Blood;2013-12-05

3. Interferon-alpha for maintenance of follicular lymphoma;Cochrane Database of Systematic Reviews;2010-01-20

4. Fludarabine;Drugs;2007

5. Phase II Study of Fludarabine Combined With Interferon-α-2a Followed by Maintenance Therapy With Interferon-α-2a in Patients With Low-Grade Non-Hodgkin’s Lymphoma;American Journal of Clinical Oncology;2002-08